Trade Cogent Biosciences, Inc. - COGT CFD
Add to favourite- Summary
- Historical Data
Spread | 0.08 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024846% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002624% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 12.19 |
Open | 12.44 |
1-Year Change | 41.52% |
Day's Range | 12.11 - 12.44 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 22, 2024 | 12.19 | 0.64 | 5.54% | 11.55 | 12.29 | 11.55 |
Oct 21, 2024 | 11.82 | 0.12 | 1.03% | 11.70 | 11.97 | 11.46 |
Oct 18, 2024 | 11.85 | 0.26 | 2.24% | 11.59 | 11.90 | 11.31 |
Oct 17, 2024 | 11.59 | 0.52 | 4.70% | 11.07 | 11.63 | 11.07 |
Oct 16, 2024 | 11.29 | -0.37 | -3.17% | 11.66 | 11.66 | 11.06 |
Oct 15, 2024 | 11.62 | 0.65 | 5.93% | 10.97 | 11.82 | 10.97 |
Oct 14, 2024 | 11.26 | 0.35 | 3.21% | 10.91 | 11.41 | 10.86 |
Oct 11, 2024 | 11.21 | 0.39 | 3.60% | 10.82 | 11.45 | 10.82 |
Oct 10, 2024 | 11.04 | 0.44 | 4.15% | 10.60 | 11.40 | 10.57 |
Oct 9, 2024 | 10.76 | 0.01 | 0.09% | 10.75 | 10.98 | 10.54 |
Oct 8, 2024 | 10.80 | 0.06 | 0.56% | 10.74 | 10.97 | 10.57 |
Oct 7, 2024 | 10.71 | -0.39 | -3.51% | 11.10 | 11.18 | 10.68 |
Oct 4, 2024 | 11.05 | 0.61 | 5.84% | 10.44 | 11.10 | 10.44 |
Oct 3, 2024 | 10.50 | 0.00 | 0.00% | 10.50 | 10.77 | 10.44 |
Oct 2, 2024 | 10.68 | 0.11 | 1.04% | 10.57 | 10.93 | 10.32 |
Oct 1, 2024 | 10.71 | -0.06 | -0.56% | 10.77 | 10.77 | 10.17 |
Sep 30, 2024 | 10.75 | -0.08 | -0.74% | 10.83 | 10.96 | 10.58 |
Sep 27, 2024 | 10.86 | 0.04 | 0.37% | 10.82 | 10.97 | 10.74 |
Sep 26, 2024 | 10.85 | 0.00 | 0.00% | 10.85 | 10.96 | 10.75 |
Sep 25, 2024 | 10.84 | -0.02 | -0.18% | 10.86 | 11.03 | 10.73 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cogent Biosciences, Inc. Company profile
About Cogent Biosciences Inc
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. The Company's most advanced program is CGT9486, a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation, as well as other mutations in KIT exon 17, to treat Systemic Mastocytosis (SM) and gastrointestinal stromal tumors (GIST). GT9486 has demonstrated clinical activity and safety results in a Phase I/II clinical trial in patients with GIST, supporting accelerated timelines to proof-of-concept in SM.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cogent Biosciences Inc revenues decreased from $7.9M to $0K. Net loss applicable to common stockholders decreased 60% to $72.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Acquired in-process research and develop decrease from $46.9M (expense) to $0K, Other income increase from $779K to $2.5M (income).
Industry: | Bio Therapeutic Drugs |
275 Wyman Street
3rd Floor
WALTHAM
MASSACHUSETTS 02451
US
News
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024Gold markets to trade
Last week, we explored the basic fundamental and technical approaches to gold trading. Having covered the key price drivers of this critical asset and how you might use data to trade it, you’re ready to assess the conditions for entry. But there are a range of markets that can effectively give you exposure to gold.
08:00, 21 October 2024US earnings seasons off to a solid start as focus shifts to tech giants
The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.
14:31, 17 October 2024ECB Preview: cooling growth and inflation call for another rate cut
Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.
12:41, 16 October 2024Australian labour force data forecast to reveal stable jobs market
Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.
07:41, 15 October 2024Applying fundamental and technical strategies to Gold Trading
Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.
08:00, 14 October 2024S&P 500 expected to deliver modest earnings growth in Q3
Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.
12:40, 11 October 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com